Re:Search Institution Members

147 Results for Members

Members

IRSS is the national health sciences research institute in Burkina Faso.

The Public Health Research Institute (PHRI) is a 76-year-old specialized center for global infectious diseases...

UF Innovate is a research institution, composed of four organizations, that actively contributes to research...

The Burnet Institute is an independent organization aiming to improve the health of vulnerable communities...

The University of Papua New Guinea, School of Medicine and Health Sciences, is a medical and health services...

Developing World Health is a not for profit charitable company, working on providing a comprehensive...

162 Results for Collaborations

Collaborations

Krupa Naran is a postdoctoral fellow at the Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, South Africa, collaborating with AstraZeneca on Tuberculosis. In particular, she meant investigating different procedures aimed at assessing the composition of a substance, in order to try to find out which would be the best drug to treat TB.

During her fellowship at the University of Melbourne with the host scientists Leanne Tilley and Matthew Dixon, Tahmina Ahmed from the International Center for Diarrheal Disease Research in Bangladesh (iccdr,b) investigated the antimalarial activity of two novel antimalarial compounds inhibitors. The compounds have been shown to have activity against enzymes that activate ubiquitin and ubiquitin-like proteins. Ms. Ahmed measured the anti-malarial activities of these drugs. This project investigated two drug candidates. Compound 1 proved more potent than chloroquine (IC50 59 nM) and artemisinin (IC50 4 nM). Antimalarial drugs that inhibit apicoplast biogenesis exhibit a delayed death mechanism of killing, however, both compounds 1 and 2 kill parasites rapidly.

Strengthening molecular surveillance and development of genomic tools that can be used in malaria control and elimination strategies in PNG, for example: Next Generation Sequencing; MinION portable sequencer. The fellowship of Dulcie Lautu from the Papua New Guinea Institute of Medical Research with the host scientist Alyssa Barry from the alter and Eliza Hall Institute of Medical Research (WEHI), Australia, aimed to enhance understanding of strategies (tools/approaches) for population genetics analysis.

The fellowship of Mohammad Shafiul Alam from the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) with the Griffith Institute for Drug Discovery (GRIDD), Australia and the host scientists Katherine Andrews and Vicky Avery provided opportunity to learn a range of drug discovery skills such as extraction and further purification of natural products, 3H-hypoxanthine uptake assays, cytotoxicity assay and phytochemical analysis. A total of 33 biota samples were obtained from the nature bank at GRIDD and screened for anti-plasmodial activity against reference strain of P. falciparum using a 72 hours isotopic micro test (3H-hypoxanthine uptake assays). After initial screening, 19 biota samples which had 50% inhibition in 10 mg/ml concentration were further investigated for selectivity index (cytotoxicity assay with Hek 293).

Malaria is a major public health threat in sub-Saharan Africa, and drug resistance is a major threat to current control efforts. Resistance to traditional antimalarials, including chloroquine and the antifolates, is widespread among the major causative parasite, Plasmodium falciparum. Artemisinin combination therapies, comprising an artemisinin derivative combined with a longer-acting partner drug such as lumefantrine or piperaquine, are the recommended treatment for falciparum malaria. However, resistance to the partner drugs is now widespread, and artemisinin resistance has recently spread throughout South-East Asia. Alarming reports of artemisinin resistance in sub-Saharan Africa are beginning to emerge, and improved methods to detect and monitor drug resistance in the field are urgently required.

The fellow Deus Ishengoma has an established research program monitoring antimalarial drug resistance in Tanzania, and aims to improve detection tools to allow routine monitoring in field settings. The host scientists Christian Doerig and Darren Creek at Monash University have developed advanced techniques for system-wide biochemical analysis of malaria parasites. These mass spectrometry and infrared (ATR-IR) spectroscopy approaches allow highly sensitive metabolomics and proteomics analyses, and may provide an alternative approach for detecting drug resistance phenotypes to established genetic tools such as mutation-dependent PCR tests.

Recent work from Darren Creek has revealed that the levels of a specific protein (Kelch13), haemoglobin-derived peptides and antioxidant molecules are associated with artemisinin-resistant parasites of South-East Asian origin (Siddiqui G, et al., J Infect Dis. In press). The collaboration wants to determine whether the abundance of these, or other specific molecules, is also associated with drug resistance in African parasites. The hypothesis that underlies this project is that metabolite and/or protein signatures of drug resistance will allow the development of point-of-care testing devices for antimalarial drug resistance.

Tedjo Sasmono from the Eijkman Institute for Molecular Biology, Indonesia, and his host scientists at the Walter and Eliza Hall Institute of Medical Research (WEHI), Australia, Diana Hansen and Alan Cowman, fixed as a primary R&D objective to establish inflammatory pathways and to identify effector cell populations and mechanisms associated with the development of severe Dengue. They used state-of-the-art technology including cytometry by time-of-flight (CyTOF) and next generation sequencing (NGS) to compare immunological pathways involved during disease progression in mild and severe Dengue. The CyTOF method combines the power of flow-cytometry with mass spectrometry. This tool enabled Tedjo Sasmono and hosts to identify the roles immune cells play in determining the severity of Dengue. The NGS methodology additionally helped researchers profile the role of various genes in the determining disease severity.

170 Results for Assets

Assets

This invention describes the design and synthesis of a multi-peptide conjugate (MPC) system containing antigens from the human malaria parasite (Plasmodium falciparium) and the Tat protein of HIV type-1 (HIV-1-Tat) for use as a subunit vaccine. The current multiple peptide conjugates (MPCs) have distinct advantages over prior MAPs because only two adjacent peptide branches are elongated on the solid phase at either the alpha or epsilon amino groups thereby allowing maximum spacing between the resin bound peptide chains. These peptides are then reacted with high performance liquid chromatography purified haloacetyl peptides to generate multiple peptide conjugates with molecular masses of 10 to 13 kDa.
The pMOD plasmid will have utility in construction of transposons for use in genetic manipulation of Mycobacteria including M.tuberculosis. Previous methods for transposon mutagenesis of Mycobacteria were cumbersome and inefficient. The pMOD plasmid is an integral part of a transposition system that is technically easy and quite efficient. This plasmid will also likely be useful for genetic manipulation of other bacteria and fungi. It would therefore be a very useful tool for molecular biologic and genetic research involving these organisms.
Malaria is estimated to cause two to four million deaths per year, and 200 to 400 million people are infected annually with the deadliest of the protozoans that cause the disease, Plasmodium falciparum. The life cycle of the malarial parasite is very complex, involving stages that reside in both humans and mosquitoes. Vaccines that are able to inhibit the transmission of the disease at a variety of stages in the complex life cycle of the malarial parasite might provide an opportunity to effectively control and possible eradicate this disease. This invention relates to the generation of transmission-blocking antibodies to two sexual stage surface antigens, Pfs 25 and Pfs 28. Two issued patents cover the use of these antigens separately as transmission-blocking vaccines. The claims of the current invention relate to the production of fusion proteins between these two surface antigens that have increased potency as immunogens and ease of manufacture.
A series of Thalidomide analogs which exhibit inhibition of angiogenesis, NIH Internal Reference E-272-2003. The subject application discloses active thalidomide analogs that exhibit enhanced potency in the inhibition of undesirable angiogenesis, and methods for using these compounds to treat angiogenesis and solid tumors. In particular, the presently disclosed method provides for inhibiting unwanted angiogenesis in a human or animal by administering to the human or animal with the undesired angiogenesis a composition comprising an effective amount of the active thalidomide analogs. According to a more specific aspect, the method involves inhibiting angiogenesis by exposing a mass having the undesirable angiogenesis to an angiogenesis inhibiting amount of one or more compounds, or pharmaceutically acceptable salts of such compounds.
A synthetic vaccine is available for testing against P. falciparum malaria. Control of malarial disease has been achieved on a limited basis in certain parts of the world; however, no vaccine presently exists that can provide protective immunity. This synthetic vaccine contains a peptide which induces the activation of cytotoxic T cells that specifically recognize and kill cells infected with malaria sporozoites.
A transmission blocking vaccine developed against malaria contains a recombinant virus, which encodes a unique portion of the sexual stage surface antigen of Plasmodium falciparum (referred to as Pfs25), or the Pfs25 protein purified from infected host cells. Mice inoculated with the recombinant virus developed antibodies capable of blocking transmission of the virus. None of the monoclonal antibodies known to block transmission recognize the reduced Pfs25 antigen. This vaccine, which induces high, long-lasting titers at low cost, can be useful for controlling malaria.